Skip to search formSkip to main contentSkip to account menu

AFQ056

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. Behind the symptoms there is a complex… 
2016
2016
Long-term use of levodopa (L-dopa) in patients with Parkinson's disease is associated with development of dyskinesia. This study… 
Highly Cited
2015
Highly Cited
2015
Apart from Huntington's disease, little is known of the genetics of autosomal dominant chorea associated with dystonia. Here we… 
2015
2015
  • Asher Mullard
  • Nature Reviews Drug Discovery
  • 2015
  • Corpus ID: 39513057
The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial… 
Highly Cited
2015
Highly Cited
2015
This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist… 
Highly Cited
2013
Highly Cited
2013
AFQ056 is a novel, selective metabotropic glutamate receptor 5 antagonist. This was a 13‐week, double‐blind, placebo‐controlled… 
Highly Cited
2011
Highly Cited
2011
An antagonist for the metabotropic glutamate receptor may improve symptoms in patients with fragile X syndrome whose FMR1… 
Highly Cited
2011
Highly Cited
2011
Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa…